固定されたツイート
$GANX Gain Therapeutics AD/PD is in 2 weeks.
reddit.com/r/pennystocks/…
English
joe iniowa
4.1K posts
joe iniowa
@Microcapreturns
Long time investor, retired from tech space
United States 参加日 Temmuz 2020
288 フォロー中1.1K フォロワー
joe iniowa がリツイート
$COYA $GANX
Thats All I Will Say Folks
Some Get it, Others Don’t
Fundamentals > Stock Price
English
joe iniowa がリツイート
🚨 Saturday Sassy Small Cap Freedom Fuel:
Gain Therapeutics $GANX
is turning heads with key conference presentations on next-gen therapies — right as macro tailwinds hit pharma hard!
This week’s updates drove solid momentum and attention.
@GainThera is building the future of precision medicine the pro-America way!
Full Details: markets.businessinsider.com/news/stocks/ga…
#Biotech #Pharma #SmallCap #MAGA #BoldStocks #StockQueen
English
@Rick_in_Miami My thoughts if they have improved 6 points after about a year of Parkinson’s time which would normally be a plus 4 that's almost a 3 year improvement. Plus getting smell back is reversing.
English
@Microcapreturns I would say it *may* be slowing progression!
Stopping or reversing progression is not yet show in the 5 months data.
Did show to lower bio-markers and keep them lower
Still good news for $GANX I may consider adding around $2.00
English
$GANX Gain Therapeutics Parkinsons showing that it continues to reverse Parkinsons after 150 days. Amazing.
Crwe World@CrweWorld
Gain Therapeutics Presents Additional Clinical and Biomarker Data from Phase 1b Clinical Study of GT-02287 and Preclinical Data from Novel Chemical Series at AD/PD 2026 $GANX crweworld.com/article/news-p…
English
joe iniowa がリツイート
Thank you to loose hands in $GANX for the early birthday present-buying this dip ahead of next weeks conf is more than prudent-nice to be long with an almost legendary group of investors and experts-truly the first disease modifying drug for any central nervous system disease 🥷
English
joe iniowa がリツイート
🚨 $GANX is a Clinical-Stage Parkinson's Play You Should Know
🔹 Novel Science Developing GT-02287, targeting GBA1-related Parkinson's disease with a first-in-class allosteric approach
🔹 Breakthrough Data Phase 1b showed 81% average reduction in a key Parkinson's biomarker — a first-ever result for a GCase modulator
🔹 Wall Street Watching 5 analysts rate it a Strong Buy with a consensus price target of $7.20
Why $GANX stands out:
🔸 Parkinson's remains one of the largest unmet needs in modern medicine with no approved disease-modifying therapies
🔸 Preclinical data shows GT-02287 reduces mitochondrial stress and enhances neuronal survival
🔸 Presenting at the AD/PD 2026 International Conference in Copenhagen this month
⚠️Clinical-stage biotech with no approved products. Early-stage investing carries significant risk. Do your own due diligence.
Communicated Disclaimer - stockresearchtoday.com/ganx/
$TLYS $AGRZ $EONR
English
$GANX Gap to fill around $3.80. News next week on Parkinson’s drug and data at AD/PD next week. Looking to take out recent high.
Walk@walktothecabin
$GANX a twitter friend likes this company
English
$GANX AD/PD conference next week. Expect biomarker data on DDC DOPA-decarboxylase improvement after only 90 days on Gains drug GT-02287. Matches UPDRS 6 point improvement showing reversing Parkinsons.
Avid Trader@RealAvidTrader
$GANX Unaffected By The Macro Craziness, Healthy Consolidation Here At 3 Month Highs
English
$GANX Gain Therapeutics presenting data on Parkinsons at AD/PD 3/18.
reddit.com/r/GreenWicks/s…
English
@MWB741 $GANX Gain Therapeutics
Great article. Here is a bunch of recent research.
Gain Therapeutics(GANX): KOL Reports : GT-02287 Shows Signs of Disease Modification
gaintherapeutics.wordpress.com/2026/01/14/gai…
English
$GANX Gain Therapeutics will be publishing DDC biomarker data at AD/PD in 2 weeks.
reddit.com/r/pennystocks/…
English
$GANX New biomarkers will be presented at AD/PD in 2 weeks.
USMCMAGA@NetLeaseTV
Now Gain Therapeutics has 2 biomarkers confirming reversal of PD symptoms! $ganx @parkinsons @ParkinsonsUK @ParkinsonsEU @CureParkinsonsT @PunchParkinsons @ParkinsonsPod @APDAParkinsons @ParkinsonsMeds @ParkinsonsNSW
English
$GANX The first Parkinsons disease modifying drug. AD/PD data coming up.
MWB74@MWB741
$GANX Update on Gain Therapeutics First, a short summary on what Gain Therapeutics is trying to do in aiming for “disease-modification”… most Parkinson’s treatments help manage symptoms like tremor or stiffness, but they do not slow the disease itself. A disease-modifying therapy is different. It aims to slow, stop, or even partially reverse the underlying disease process, not just mask symptoms. Today, there are no approved disease-modifying treatments for Parkinson’s disease. Gain Therapeutics ($GANX) believes its drug candidate GT-02287 is showing early signs of disease modification — which, if confirmed in larger studies, would represent a major breakthrough not only for Parkinson’s, but potentially for related diseases such as Lewy body dementia, Gaucher disease, and possibly Alzheimer’s disease. February Corporate Update: Gain released an updated corporate deck recently (link in comments), and there are two Phase 1b findings that greatly change the risk profile going into Phase 2: GluSph reduction (upstream biological signal) About one-third (maybe more) of patients entered the Phase 1b with elevated CSF glucosylsphingosine (GluSph), a toxic lipid linked to dysfunction in Parkinson’s (and Gaucher’s disease). In this subgroup, 100% of patients saw GluSph reduced toward normal, with an average ~81% reduction after 90 days on GT-02287. Statistically significant functional improvement That same GluSph-elevated subgroup also showed a statistically significant improvement in combined MDS-UPDRS Parts II + III, with a mean improvement of 6.17 points (p < 0.05). This was actual improvement, not just “less worsening,” and it occurred over ~90 days — which is unusual for programs aiming at disease modification in PD. The “statistical significance” means that within that GluSph-elevated subgroup, the probability that the observed UPDRS clinical improvements occurred by chance alone is less than 5% (p < 0.05). In other words, If GT-02287 had no real effect in that GluSph-elevated group, the probability of observing an improvement this large (or larger) purely by chance is less than 5%. This reduction in GluSph and link to clinical improvements has never been seen before in Parkinson’s patients. If 30% is representative of the number of Parkinson’s patients who have elevated levels of GluSph, this is a giant number. Importantly, it also does not mean (1) that patients who do not have elevated levels will not develop elevated levels in the future, and (2) that GT-02287 would not be beneficial to individuals who do not have elevated GluSph levels. This (very large) sub-population simply looks like low-hanging fruit. For phase 2, this matters because: • It links mechanism to biomarkers to function in humans, not just animals • It identifies a defined responder population, which allows for clear phase 2 planning and setting it up for success • It reduces reliance on noisy, purely clinical endpoints by anchoring outcomes to GluSph • It lowers the chance of a “clean safety but messy efficacy” Phase 2 readout This is what big pharma teams look for when assessing whether early PD signals are real or just statistical noise. The company is explicitly framing this as “translation” from animal models to clinical success in humans. Upstream correction of cellular dysfunction with a strong correlation to functional benefits. CEO Gene Mack succinctly summarized what they are seeing with GT-02287 in a BioSpace interview a few weeks back: “Rather than simply trying to boost enzyme activity in the lysosome, GT-02287 stabilizes GCase folding and trafficking throughout the cell, restoring function across multiple compartments, including those critical to mitochondrial health. That matters because Parkinson’s can be seen as a disease of cellular stress, impaired waste clearance, and energy failure.” 16 out of 19 of the patients who completed the initial 90 days elected to continue into the extension study, despite the further testing and lumber puncture. If they weren’t experiencing benefits, it is unlikely they’d choose to continue. Data from the extension will show whether improvements continue over time. They should already have the 180 day blood and UPDRS data, and judging from the CEO’s statement above, the data continues to support disease-modification. Despite the recent surge, the share price is considerably lower than it was in mid-December pre-data release. Most people will look at this and assume that something must have been wrong. But the market gets misprices companies all the time, especially in small biotechs. To me, this is a great opportunity to buy what might turn out to be the first and most important disease-modifying drug in neurodegenerative disease history. @LouBasenese @PhilipEtienne @RealAvidTrader @BiotechStockRsr @odibro @yaireinhorn @thebiotechforum @BiopharmIQ @BPharmCatalyst @SupNovaTrading @StocksPursuit @Microcapreturns @dixielee1969 @fundmyfund @makedatbread88 @SheffStation @bwsm12702 @TopStockAlerts1
English
$GANX Data at AD/PD in March showing reversing Parkinson's.
Top Stock Alerts@TopStockAlerts1
$GANX Rare disease oncology angle with focused pipeline execution. Lean structure keeps milestones meaningful to valuation. Any regulatory or partnership update could quickly reset perception. Are traders positioning ahead of the next catalyst?
English
Gain Therapeutics $GANX GT-02287 showing efficacy after only 90 days in phase 1b.
drug hunter@drughunter_com
Drugging GCase: The Challenges With Targeting A Multi-Compartment Enzyme | drughunters.com/3OeJgqD GCase (encoded by GBA1) is a pivotal genetic risk factor in Parkinson’s and Gaucher’s diseases, where folding/trafficking defects disrupt lysosomal lipid metabolism and drive aggregation. In this review we will highlight: -What made drugging this target so challenging? -How active-site pharmacological chaperones showed promise in rescuing misfolded enzymes but faltered due to lysosomal inhibition -The next generation of CNS-penetrant allosteric activators, including pariceract (BIA 28-6156), GT-02287, and VQ-101 that are currently in clinical trials to test if non-inhibitory modulation can deliver on the promise of the GCase mechanism Read it on Drug Hunter: drughunters.com/3OeJgqD
English
$GANX Gain Therapeutics At the 52.40 mark of yesterday's Sachs conf. CEO says we are getting biomarker correlation we have been waiting data on.
youtu.be/Hvsllm583Vc?si…
YouTube
English
joe iniowa がリツイート
From opening new therapeutic mechanisms to repairing neuronal damage, investigational molecules from Ventyx Therapeutics, AC Immune, Gain Therapeutics and more could shape the future of Parkinson’s disease treatment.
#parkinsons #pharma #biospace
hubs.li/Q040hgLC0
English
$GANX Gain Therapeutics At some point people are going to figure out exactly how valuable their ability to not only stop Parkinson's but reverse it.
reddit.com/r/pennystocks/…
English